Methodological issues in designing a randomized controlled trial for psychotic depression: The STOP-PD study

Psychiatric Annals

Volumn 36, Issue 1, 2006, Pages 57-64

  Meyers, Barnett S ^a   Peasley Miklus, Catherine ^a   Flint, Alastair J ^a   Mulsant, Benoit H ^a   Rothschild, Anthony J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 31644450499     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/00485713-20060101-04     Document Type: Review

References (43)

1. Avery D, Lubrano A. Depression treated with imipramine and ECT: the DeCarolis study reconsidered. Am J Psychiatry. 1979;136(4B):559-562.
2. Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001;285(10):1299-1307.
3. Petrides G, Fink M, Husain MM, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT. 2001;17(4):244-253.
4. Prudic J, Olfson M, Sackeim HA. Electro-convulsive therapy practices in the community. Psychol Med. 2001;31(5):929-934.
5. Prudic J, Olfson M, Marcus SC, Fuller RB, Sackeim HA. Effectiveness of electroconvulsive therapy in community settings. Biol Psychiatry. 2004;55(3):301-312.
6. Spiker DG, Weiss JC, Dealy RS, et al. The pharmacological treatment of delusional depression. Am J Psychiatry. 1985;142(4):430-436.
7. Flint AJ, Rifat SL. Two-year outcome of psychotic depression in late life. Am J Psychiatry. 1998;155(2):178-183.
8. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2000;157(4 Suppl):1-45.
9. Mulsant BH, Sweet RA, Rosen J, et al. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. J Clin Psychiatry. 2001; 62(8):597-604.
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders [text revision]. 4th ed. Washington, DC: American Psychiatric Publishing; 2000.
11. Meyers BS, English J, Peasley-Miklus C, et al. Delusions associated with late-life major depression: diagnostic and therapeutic considerations. Scientific Proceedings of the 4th Annual Meeting of the International College of Geriatric Psychoneuropharmacology. October 14-16, 2004; Basel, Switzerland.
12. Coryell W, Zimmerman M. Demographic, historical, and symptomatic features of the nonmanic psychoses. J Nerv Ment Dis. 1986; 174(10):585-592.
13. Anton RF, Burch E. Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression. Am J Psychiatry. 1990;147(9):1203-1208.
14. Parker G, Hadzi-Pavlovic D, Hickie I, et al. Psychotic depression: a review and clinical experience. Aust N Z J Psychiatry. 1991; 25(2):169-180.
15. Meyers BS. Treatment of psychotic depression. In: Nelson JC, ed. Geriatric Psychopharmacology. New York, NY: March Dekker; 1998:99-114.
16. Glassman A, Roose S. Delusional depression. A distinct clinical entity? Arch Gen Psychiatry. 1981;38(4):424-427.
17. Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry. 1992;149(6):733-745.
18. Mulsant BH, Haskett RF, Prudic J, et al. Low use of neuroleptic drugs in the treatment of psychotic major depression. Am J Psychiatry. 199;154(4):559-561.
19. Spiker D, Kupfer D. Placebo response rates in psychotic and nonpsychotic depression. J Affect Disord. 1988;14(1):21-23.
20. Rothschild AJ, Williamson DJ, Tohen MF, et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol. 2004;24(4):365-373.
21. Hamilton M. A rating scale for depression. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62.
22. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001; 158(1):131-134.
23. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079-1088.
24. Rothschild A, Bates KS, Boehringer KL, Syed A. Olanzapine response in psychotic depression. J Clin Psychiatry. 1999;60(2):116-118.
25. Konig F, von Hippel C, Petersdorff T, et al. First experiences in combination therapy using olanzapine with SSRIs (citalopram, paroxetine) in delusional depression. Neuropsychobiology. 2001;43(3):170-174.
26. Matthews JD, Bottonari KA, Polania LM, et al. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. J Clin Psychiatry. 2002; 63(12):1164-1170.
27. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000: 57(10):968-976.
28. Gatti F, Bellini L, Gasperini M, et al. Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry. 1996;153(3): 414-416.
29. Zanardi R, Franchini L, Gasperini M, Perez J, Smeraldi E. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry. 1996;153(12):1631-1633.
30. Zanardi R, Franchini L, Serretti A, Perez J, Smeraldi E. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. J Clin Psychiatry. 2000;61(1):26-29.
31. Griest J, Chouinard G, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1995;52(4):289-295.
32. Rothschild AJ, Phillips KA. Selective serotonin reuptake inhibitors and delusional depression. Am J Psychiatry. 1999;156(6):977-978.
33. Simpson GM, El Sheshai A, Rady A, Kingsbury SJ, Fayek M. Sertraline as monotherapy in the treatment of psychotic and nonpsychotic depression. J Clin Psychiatry. 2003;64(8):959-965.
34. Johnson J, Horwath E, Weissman MM. The validity of major depression with psychotic features based on a community study. Arch Gen Psychiatry. 1991;48(12):1075-1081.
35. Roose SP, Glassman AH, Walsh BT, Woodring S, Vital-Herne J. Depression, delusions, and suicide. Am J Psychiatry. 1983;140(9): 1159-1162.
36. Georgotas A, McCue RE, Hapworth W, et al. Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly. Biol Psychiatry. 1986;21(12):1155-1166.
37. Reynolds CF, Frank E, Kupfer DJ, et al. Treatment outcome in recurrent major depression: a post hoc comparison of elderly ("young old") and midlife patients. Am J Psychiatry. 1996;153(10):1288-1292.
38. Bump GM, Mulsant BH, Pollock BG, et al. Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly. Depress Anxiety. 2001;13(1):38-44.
39. Opdyke KS, Renolds CF 3rd, Frank E, et al. Effect of continuation treatment on residual symptoms in late-life depression: how well is "well"? Depress Anxiety. 1996-97;4(6):312-319.
40. Roose SP, Sackeim HA. Clinical trials in late-life depression: revisited. Am J Geriatr Psychiatry. 2002;10(5):503-505.
41. David AS. Insight and psychosis. Br J Psychiatry. 1990 Jun;156:798-808.
42. Sharp HM, Fear CF, Williams JM, et al. Delusional phenomenology - dimensions of change. Behav Res Ther. 1996;34(2):123-142.
43. Rothschild AJ. Challenges in the treatment of depression with psychotic features. Biol Psychiatry. 2003;53(8):680-690.